Company: NIVFW
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001213900-25-033966
Chunk: 43

Company: NewGenIvf Group Ltd
Filing Date: 2025-04-22
Form: 20-F
Item: Item 3
Chunk 43
---
 regulations and subsidies and on April 2,
2025, announced new tariffs on many U. S. trading partners, including a universal baseline tariff of 10% on all imported goods, and country
specific tariffs such as an additional 34% tax on imports from China (leading to an effective rate of 54% when combined with existing
tariffs) and 20% on products from the E. U. Specific products that are being tariffed, such as automobiles, were to be exempted from the
new tariffs, and tariffs on products such as pharmaceutical drugs were to be announced at a later date. Following a period of market turbulence,
on April 9, 2025, President Trump announced a 90-day pause to the tariffs announced on April 2, 2025 for most countries. Countries subject
to the pause on the tariffs are still to be subject to the baseline 10% tariff. This consequently lowers the tariff rate for the E. U.,
Japan, and South Korea, among other countries. However, U. S. President Trump announced an increased tariff rate against Chinese imports
of a minimum 145%. These and other tariffs and countermeasures could increase the cost of equipment necessary for our operations, disrupt
global supply chains and create additional operational challenges. Additionally, ongoing trade tensions and uncertainty regarding future
trade policies could negatively impact global economic conditions and consumer confidence, further affecting our business performance.

Any litigation against NewGenIvf could be
costly and time-consuming to defend and could harm its business, financial condition and results of operations.

NewGenIvf has in the past
and may in the future become subject to regulatory actions, litigation, disputes, or claims of various types, legal proceedings and claims
that arise in the ordinary course of business, such as claims brought by its clients or vendors in connection with commercial disputes
or employment claims made by its current or former employees, as well as claims brought by relevant regulatory authorities or NewGenIvf’s
competitors, patients, employees, or other third parties against NewGenIvf. NewGenIvf is unable to predict the outcome of any of these
legal proceedings. Such regulatory actions, disputes, allegations, complaints, or legal proceedings may damage NewGenIvf’s reputation,
evolve into litigation, or otherwise have a material adverse impact on NewGenIvf’s reputation and business. Such proceedings might
result in substantial costs, regardless of the outcome, and may significantly divert management’s attention and resources from operating
New